00Read later0Read MoreGilead-Backed Aspen Neuroscience Shares Decline 2% After US IPOBloomberg Markets·Angel Adegbesan·11 days ago#dmiFOuSm#bloomberg#business#aspen#neuroscience#clinical+5 more🧰Tag tools✨Add tagReading 0:0015s thresholdBookmarkAspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering. Expand ContentAnonymous readers can preview up to 1024 characters here. Log in to unlock the full article once ingest succeeds.